# PEER REVIEW AUDIT REPORT: Manuscript 4
## Clinical Burden of AMR-BSI in Indian ICUs

**Date:** January 7, 2026  
**Manuscript:** Clinical Burden of Antimicrobial-Resistant Bloodstream Infections in Indian ICUs (2021-2024)  
**Target Journal:** IJMR Research Brief

---

## REVIEWER 1: Epidemiologist / Public Health Expert

### Overall Assessment
**Recommendation:** Accept with Minor Revisions

The manuscript provides valuable surveillance synthesis on AMR clinical burden. The declining mortality trend is noteworthy.

### Critical Issues
1. **Sample Size Clarification (MODERATE)**
   - N=14 surveillance data points is low; clarify this represents aggregated network data, not individual patients
   - Recommend adding: "These 14 data points represent aggregate outcomes from surveillance networks covering >39 hospitals"

2. **Ecological Fallacy Warning (MODERATE)**
   - Add explicit statement: "As aggregate surveillance data, individual patient-level outcomes cannot be inferred"

### Minor Issues
3. **Confidence Intervals**
   - Table 1 lacks confidence intervals for mortality estimates
   - Consider adding where calculable

4. **Temporal Trend Causality**
   - Declining mortality claim needs caveat about potential confounders (COVID-19 impact, reporting changes)

---

## REVIEWER 2: Clinical Microbiologist / ID Specialist

### Overall Assessment
**Recommendation:** Accept with Minor Revisions

Clinically relevant analysis highlighting critical resistance patterns. Some technical refinements needed.

### Critical Issues
1. **Resistance Definition Clarity (MODERATE)**
   - Specify: Are these ICU-specific rates or hospital-wide?
   - Clarify breakpoint standards used (CLSI vs EUCAST) for each year

2. **Colistin Susceptibility Gap (MODERATE)**
   - Given high carbapenem resistance, colistin susceptibility data would strengthen clinical utility
   - If unavailable, acknowledge as limitation

### Minor Issues
3. **A. baumannii Clinical Implications**
   - Expand on why A. baumannii resistance is particularly concerning (limited treatment options, environmental persistence)

4. **Stewardship Recommendations**
   - Strengthen with specific actionable recommendations (e.g., carbapenem-sparing protocols, rapid diagnostics)

---

## SUMMARY OF REQUIRED ENHANCEMENTS

| # | Enhancement | Priority | Location |
|---|------------|----------|----------|
| 1 | Clarify N=14 represents aggregate network data | High | Methods |
| 2 | Add ecological fallacy caveat | High | Discussion |
| 3 | Note breakpoint standards (CLSI/EUCAST) | Medium | Methods |
| 4 | Acknowledge colistin data gap as limitation | Medium | Discussion |
| 5 | Expand A. baumannii clinical implications | Medium | Discussion |
| 6 | Add specific stewardship recommendations | Medium | Conclusions |
| 7 | Add temporal confounding caveat | Low | Discussion |

---

## OVERALL VERDICT

âœ… **PUBLISHABLE after incorporating 7 minor enhancements**

The manuscript is scientifically sound and clinically relevant. The identified issues are minor and can be addressed through targeted text additions without requiring new analyses.
